The stock of Concordia International Corp (NASDAQ:CXRX) is a huge mover today! The stock decreased 13.99% or $0.4 on November 23, hitting $2.46. About 1.60 million shares traded hands. Concordia International Corp (NASDAQ:CXRX) has declined 92.42% since April 22, 2016 and is downtrending. It has underperformed by 97.83% the S&P500.
The move comes after 8 months negative chart setup for the $145.91 million company. It was reported on Nov, 24 by Barchart.com. We have $2.26 PT which if reached, will make NASDAQ:CXRX worth $11.67 million less.
Analysts await Concordia International Corp (NASDAQ:CXRX) to report earnings on March, 22. They expect $-0.03 EPS, down 102.78% or $1.11 from last year’s $1.08 per share. After $-0.33 actual EPS reported by Concordia International Corp for the previous quarter, Wall Street now forecasts -90.91% EPS growth.
Concordia International Corp (NASDAQ:CXRX) Ratings Coverage
Out of 9 analysts covering Concordia Healthcare Corp. (NASDAQ:CXRX), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. $105 is the highest target while $13 is the lowest. The $57.50 average target is 2237.40% above today’s ($2.46) stock price. Concordia Healthcare Corp. has been the topic of 18 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The rating was maintained by Scotia Capital with “Sector Outperform” on Friday, October 16. The rating was upgraded by Scotia Capital on Monday, September 19 to “Sector Perform”. Scotia Capital maintained the shares of CXRX in a report on Tuesday, September 29 with “Sector Outperform” rating. The firm has “Buy” rating by Laurentian given on Tuesday, March 29. IBC initiated Concordia International Corp (NASDAQ:CXRX) on Monday, November 30 with “Sector Perform” rating. As per Friday, October 16, the company rating was maintained by S&P Research. The rating was maintained by Canaccord Genuity on Tuesday, August 11 with “Buy”. The stock of Concordia International Corp (NASDAQ:CXRX) earned “Hold” rating by GMP Securities on Monday, August 15. The rating was downgraded by IBC to “Underperformer” on Monday, August 15. The company was initiated on Monday, June 6 by Goldman Sachs.
According to Zacks Investment Research, “Concordia International Corp is a diverse pharmaceutical company which focused on legacy pharmaceutical products and orphan drugs. The company also markets orphan drugs through its Orphan Drug Division, currently consisting of Photofrin(R) for the treatment of certain rare forms of cancer, which is currently undergoing testing for potential new indications. Concordia International Corp, formerly known as Concordia Healthcare Corp, is headquartered in Oakville, Canada.”
More news for Concordia International Corp (NASDAQ:CXRX) were recently published by: Prnewswire.com, which released: “Concordia International Corp. Announces CEO Transition Plan” on October 21, 2016. Finance.Yahoo.com‘s article titled: “Concordia International Corp. Announces Release Date for Third Quarter 2016 …” and published on October 26, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.